Welcome to magic mushroom shop
Season Sale: Time to refresh your Mind. Shop Now
Welcome to magic mushroom shop
Season Sale: Time to refresh your Mind. Shop Now

Psilocybin Therapy Research

Psilocybin Therapy Research: What Clinical Trials Show About Depression, Anxiety, and PTSD

Medical disclaimer: This article is for general education and is not medical advice. Psilocybin is a controlled substance in most countries. Never start, stop, or change treatment without a qualified clinician.

For decades, psychedelics were treated as a research dead end. That has changed. Over the past fifteen years, universities and drug developers have run clinical trials to test whether psilocybin, the main psychoactive compound in “magic mushrooms,” can help people with depression, anxiety, and other conditions that are hard to treat.

The field has reached a turning point. Late-stage  trials of a synthetic psilocybin formulation in treatment-resistant depression have reported positive results, and a regulatory filing with the U.S. FDA is underway. At the same time, the evidence is still young, many studies are small, and the strongest claims online go well beyond what the data show.

This guide explains what psilocybin therapy research actually shows, where the evidence is strong, where it is thin, and what the risks are.

What Is Psilocybin Therapy?

Psilocybin is a naturally occurring compound found in more than 200 species of mushrooms. After it is swallowed, the body converts it into psilocin, the active molecule. Psilocin binds to serotonin receptors in the brain, especially the 5-HT2A receptor, and temporarily alters perception, mood, and sense of self. Imaging studies suggest it also changes how different brain networks communicate, though researchers are still working out how this relates to symptom relief.

In research settings, psilocybin is not handed out like a standard pill. Most trials use psilocybin-assisted psychotherapy, which has three parts:

  • Preparation: One or more sessions with trained clinicians to screen participants, build trust, and explain what to expect.
  • Dosing session: A single supervised session, often 6 to 8 hours long, in a calm room with two monitors present. Participants are usually encouraged to lie down, wear eye shades, and listen to music.
  • Integration: Follow-up sessions to help the person make sense of the experience and apply it in daily life.

This structure matters. The drug and the surrounding therapy are studied together, so results from a supervised trial should not be assumed to apply to unsupervised use.

What Clinical Trials Reveal About Psilocybin for Depression

Depression is where the evidence is deepest, so this section covers the most ground. Searches for psilocybin therapy for depression and is psilocybin therapy effective for depression? are among the most common, and the honest answer is: promising, but still being confirmed.

Early and mid-sized studies

  • Carhart-Harris et al. (2016, Lancet Psychiatry): An open-label pilot of 12 people with treatment-resistant depression. Symptoms dropped substantially in the first weeks. With no control group, the results were a signal worth testing rather than proof.
  • Davis et al. (2021, JAMA Psychiatry): A randomized, wait-list-controlled trial of 24 adults with major depressive disorder at Johns Hopkins. Two psilocybin sessions with supportive therapy produced large reductions in depression scores compared with delayed treatment. At the 4-week follow-up, about 54% of participants were in remission. The trial was small and participants knew whether they were being treated.
  • Raison et al. (2023, JAMA): A randomized, double-blind trial of 104 adults with major depression comparing a single 25 mg dose of psilocybin with niacin (an active placebo that causes a flushing sensation). Depression scores at day 43 were significantly lower with psilocybin, by about 12 points on the MADRS scale.

Psilocybin vs. a standard antidepressant

Carhart-Harris et al. (2021, New England Journal of Medicine) compared two psilocybin doses with six weeks of daily escitalopram in 59 people with moderate to severe depression. On the primary measure, the difference between the groups was not statistically significant. Several secondary measures favored psilocybin, but those were not corrected for multiple comparisons and should be read cautiously. This is a good reminder that “promising” does not mean “proven better than existing treatment.”

Research on treatment-resistant depression

Goodwin et al. (2022, New England Journal of Medicine) was a Phase 2b, double-blind, dose-finding trial of Compass Pathways’ COMP360 in 233 people with treatment-resistant depression. A single 25 mg dose reduced depression scores by about 6.6 points more than a 1 mg control dose at week 3. The 10 mg dose did not show a significant difference. Adverse events were more common with the higher doses, and some participants reported suicidal ideation or self-injury during follow-up, so close monitoring is needed.

Phase 3 results (2025–2026)

In 2025 and 2026, Compass Pathways reported topline results from two Phase 3 trials of COMP360 in treatment-resistant depression, according to the company and trade press:

  • COMP005 enrolled 258 patients at 32 U.S. sites and met its primary endpoint, making it the first Phase 3 trial of a classic psychedelic to report positive efficacy results. An independent safety board found no new safety concerns.
  • COMP006 tested two fixed doses of COMP360 and reported a positive primary endpoint at week 6, followed by 26-week data in July 2026. The company reported that about 39% of participants had a clinically meaningful response after two doses, compared with about 25% after a single dose in COMP005, and that benefits lasted roughly six months on average for responders.

Compass has said it plans to complete its FDA New Drug Application in the fourth quarter of 2026, with a possible launch in the first half of 2027, subject to FDA approval and DEA rescheduling. These are sponsor-reported results, announced ahead of peer-reviewed publication at the time of writing, and timelines can change. Treat them as encouraging, not final.

How big and how long?

Study

Design

Participants

Headline finding

Davis 2021

Randomized, wait-list

24

Large symptom reduction; ~54% remission at 4 weeks

Carhart-Harris 2021

Randomized, vs escitalopram

59

No significant difference on primary measure

Raison 2023

Randomized, double-blind, niacin control

104

Significant reduction at day 43

Goodwin 2022

Phase 2b, dose-finding

233

25 mg beat 1 mg at week 3

COMP005 / COMP006

Phase 3 (sponsor-reported)

258 / ~580

Primary endpoints met; effects reported up to 26 weeks

A 12-month follow-up of the Johns Hopkins depression trial (Gukasyan et al., 2022, Journal of Psychopharmacology) found that many participants maintained improvement. Even so, long-term durability beyond a year is not well established, and some people relapse.

Psilocybin Therapy for Anxiety

The strongest anxiety data come from people facing life-threatening illness, usually cancer.

  • Grob et al. (2011, Archives of General Psychiatry): A small pilot of 12 patients with advanced-stage cancer and anxiety. It suggested psilocybin was feasible and might reduce anxiety.
  • Griffiths et al. (2016, Journal of Psychopharmacology): A double-blind crossover trial at Johns Hopkins with 51 cancer patients. A high dose produced large reductions in clinician- and self-rated depression and anxiety compared with a very low dose, and around 80% of participants showed clinically significant improvement at the 6-month follow-up.
  • Ross et al. (2016, Journal of Psychopharmacology): A double-blind crossover trial at NYU with 29 patients, reporting rapid and sustained reductions in anxiety and depression, along with improvements in existential distress.

These trials are among the most carefully designed in the field, but they are small and focused on a specific group. They do not show that psilocybin works for generalized anxiety disorder, social anxiety, or panic disorder in the general population. Other compounds, such as LSD, are being tested for generalized anxiety, but that is separate research. The honest summary: psilocybin therapy shows meaningful promise for anxiety in cancer-related distress, and broader use remains unproven.

Can Psilocybin Therapy Help With PTSD?

This is the section where readers most often come away with the wrong impression, so precision matters.

The best-known psychedelic research on PTSD involves MDMA, not psilocybin. A Phase 3 trial published in Nature Medicine (Mitchell et al., 2021, 90 participants) found that about two-thirds of people receiving MDMA-assisted therapy no longer met PTSD criteria afterward, versus about one-third on placebo with therapy. Even so, the FDA declined to approve MDMA-assisted therapy in August 2024, citing concerns about trial design, blinding, and safety data. That outcome is a useful lesson for the whole field.

Research on psilocybin for PTSD is much earlier. It consists mainly of small pilot studies and ongoing early-phase trials, and no completed large randomized trial has established that it works. Researchers have proposed theories, such as that psilocybin may increase emotional flexibility and make it easier to process traumatic memories, but a theory is not a clinical outcome.

So what does science say about psilocybin therapy for PTSD? That it is a reasonable thing to study, and that we do not yet know whether it works.

What Do Major Research Institutions Say?

  • Johns Hopkins Center for Psychedelic and Consciousness Research: Its group has published foundational work on psilocybin for cancer-related distress and major depression, and has emphasized careful screening, trained monitors, and a controlled setting.
  • Imperial College London’s Centre for Psychedelic Research: Its researchers led the early open-label work in treatment-resistant depression and the head-to-head trial with escitalopram, and have studied brain imaging effects of psilocybin.
  • Other universities and medical centers: NYU Langone, the University of Alabama at Birmingham, UCSF, and groups in Europe and Australia have contributed trials and safety data across several conditions.
  • Regulators: The FDA has granted Breakthrough Therapy designation to psilocybin programs for treatment-resistant depression and major depressive disorder, which speeds development but is not an approval or a statement that the drug works.

Most of these groups stress the same message: promising early evidence, with a strong need for larger and longer trials.

Potential Benefits and Risks of Psilocybin Therapy

Possible benefits

  • Substantial reductions in depressive symptoms in some trial participants, sometimes after only one or two dosing sessions.
  • Effects that, in several studies, appeared within days to weeks and persisted for months.
  • Reports of increased emotional openness and changes in how people relate to difficult experiences. 

Short-term effects and risks

  • Common during dosing: Nausea, headache, anxiety, confusion, changes in blood pressure and heart rate, and intense visual or emotional experiences. In the Phase 3 reports, most such events were temporary and occurred mainly on the day of dosing.
  • Psychological distress: Some people have frightening or overwhelming experiences, sometimes called a “bad trip.” In clinical settings, clinicians are present to support participants through this.
  • Suicidal thoughts: Some trials have reported suicidal ideation or self-injury in participants after treatment. Whether psilocybin contributes to this is still being studied, which is one reason monitoring is built into trials.
  • Higher-risk groups: People with a personal or family history of psychosis or bipolar I disorder are typically excluded from trials because psychedelics may trigger or worsen these conditions. Certain medications, including lithium and some antidepressants, can also interact with psilocybin or alter its effects.

Why screening and supervision matter

Trials screen out people at higher risk, prepare participants in advance, and keep trained monitors present throughout. Those protections are a major part of why results in trials cannot simply be carried over to unsupervised use.

Psilocybin Retreats for Anxiety: What Should You Know?

Because psilocybin retreat for anxiety is a frequent search, it is worth being direct: a commercial retreat is not the same as clinical psilocybin therapy.

 

Clinical trial / regulated therapy

Commercial retreat

Screening

Medical and psychiatric screening, medication review

Varies widely; sometimes a questionnaire only

Staff

Trained clinicians, defined protocols

Qualifications vary; some facilitators are unlicensed

Substance

Pharmaceutical-grade, measured dose

Often natural mushrooms with variable potency

Oversight

Ethics boards, regulators, safety reporting

Often little or none

Evidence

Studied in controlled trials

Not tested in the same way

If you are considering a retreat, ask:

  • What medical and psychiatric screening is done, and by whom? Is there a clinician on site?
  • What are the facilitators’ qualifications and training?
  • What happens if something goes wrong? Is there an emergency plan?
  • Is it legal where it takes place? Laws differ by country and, in the U.S., by state.
  • What does the retreat promise? Be wary of claims to cure anxiety or depression. Attending a retreat does not guarantee a therapeutic benefit, and some people are worse off afterward.

If you take medication for a mental health condition, speak with your prescriber before making any decision. Do not stop prescribed medication on your own.

What Are the Limitations of Current Research?

Even with encouraging results, the evidence has real weaknesses:

  • Small samples: Many foundational trials enrolled fewer than 100 people.
  • Blinding problems: It is hard to hide a powerful psychedelic experience from a participant who receives it. Participants and clinicians often guess correctly who got the drug, which can inflate results.
  • Expectancy effects: People who join psychedelic trials often hope or expect it will work, and expectation alone can influence outcomes.
  • Limited diversity: Trial participants have often been mostly white, educated, and previously interested in psychedelics, so results may not generalize.
  • Short follow-up: Most studies follow participants for weeks to months. Long-term safety and durability are less clear.
  • Therapy confounds: Because psychotherapy is part of the treatment, it is difficult to separate the effect of the drug from the effect of the support around it.
  • Sponsor-reported data: Some of the newest findings come from company announcements and have not yet gone through full peer review.

The Future of Psilocybin Therapy Research

Several questions will shape the next phase:

  • Peer-reviewed Phase 3 data and regulatory decisions: Whether the FDA approves a psilocybin therapy, with what labeling, and under what safety program.
  • Who benefits most: Trials are starting to ask which patients respond, and which are at greater risk.
  • How much therapy is needed: Researchers are testing whether shorter or less intensive support can work, which would affect cost and access.
  • Other conditions: Studies are exploring psilocybin for PTSD, alcohol use disorder, eating disorders, and other conditions, but results are early.
  • Long-term outcomes: Longer follow-up and repeat dosing are needed.

If a therapy is approved, access, cost, clinic capacity, and the logistics of multi-hour sessions will all matter. Progress will likely be gradual, not a sudden cure.

Frequently Asked Questions

What is psilocybin therapy used for?

In research, it is being studied for treatment-resistant depression, major depressive disorder, anxiety linked to life-threatening illness, and, more tentatively, PTSD, substance use disorders, and other conditions. It is not yet an approved treatment in the United States.

Does psilocybin therapy work for depression?

Several randomized trials, including a large Phase 2b study and sponsor-reported Phase 3 studies, show symptom reductions in some participants. It did not clearly outperform an antidepressant in one head-to-head trial, and it does not work for everyone.

Can psilocybin help with anxiety?

The best evidence is for anxiety and depression in people with cancer or other life-threatening illness. Evidence for other anxiety disorders is limited.

Is psilocybin therapy effective for PTSD?

It is not yet known. Psilocybin research for PTSD is early. The more advanced PTSD research involves MDMA, which the FDA declined to approve in 2024.

How long do the effects of psilocybin therapy last?

In some trials, improvements lasted weeks to months, and a 12-month follow-up of one depression study found that many participants maintained benefit. Durability varies, and some people relapse.

Is psilocybin therapy safe?

In supervised clinical settings with screening, it has generally been well tolerated, with mostly short-lived side effects such as nausea, headache, and anxiety. Risks include psychological distress and, in some trials, suicidal thoughts. It is not appropriate for everyone, particularly people with a history of psychosis or bipolar I disorder.

What is the difference between psilocybin therapy and a psychedelic retreat?

Clinical therapy involves medical screening, trained clinicians, pharmaceutical-grade doses, and regulatory oversight. Retreats vary widely in safety standards and have not been tested in the same way.

Is psilocybin therapy legal?

It depends on where you live. Psilocybin remains a Schedule I substance under U.S. federal law, though Oregon and Colorado have created regulated programs, and Australia allows specially authorized psychiatrists to prescribe it for certain conditions. Laws change, so check current local rules.

Leave a Reply

Your email address will not be published. Required fields are marked *

Comment

Shop
Search
Account
0 Cart
Shopping Cart

Your cart is empty

You may check out all the available products and buy some in the shop

Return to shop